Fibrosis, inflammation, and osteophyte formation in post-traumatic osteoarthritis
Project Number5K99AR081894-02
Contact PI/Project LeaderKNIGHTS, ALEXANDER JOHN
Awardee OrganizationUNIVERSITY OF MICHIGAN AT ANN ARBOR
Description
Abstract Text
Post-traumatic osteoarthritis (PTOA) is a degenerative joint disease that arises after injury and affects millions
worldwide. There are currently no disease-modifying treatments. PTOA is a complex, multi-tissue joint disease
characterized by pain, cartilage degradation, synovial inflammation and fibrosis, and formation of ectopic bone
growths called osteophytes. The inherent complexity of this disease is a barrier to developing effective
treatments, as little is known about the intricate tissue crosstalk that underlies PTOA progression. Our long-
term goal is to uncover and comprehensively characterize cellular and molecular mechanisms central to key
pathological sequalae of PTOA: synovial fibrosis, inflammation, and osteophyte formation. We will focus on
canonical Wnt/β-catenin (cWnt) signaling. cWnt overactivation has recently been implicated as a driving factor
of arthritis. Our data show that the cWnt signaling agonist R-spondin 2 (Rspo2) is strongly induced in multiple
joint tissues during PTOA, and that Rspo2 alone is sufficient to induce pathological features characteristic of
PTOA. Using single-cell RNA-seq, we profiled synovium of mice with PTOA and found that Rspo2 is produced
by synovial lining fibroblasts. We identified a novel population of pro-fibrotic cells that arise after injury and
express Lgr cell surface receptors for Rspo2. We showed that synovial fibroblasts respond to Rspo2 by
secreting cytokines that in turn activate pro-inflammatory macrophages (known to drive synovial pathology in
PTOA). Single-cell profiling also revealed a novel subset of injury-induced, Lgr-expressing osteochondral
progenitors in synovium, which we propose give rise to osteophytes. We hypothesize that Rspo2-driven cWnt
signaling mediates pathological crosstalk between joint-resident cell types to potentiate PTOA. To test this, our
aims in the K99 phase are to: 1) determine the role of Rspo2-driven cWnt signaling in the emergence and
function of pro-fibrotic synovial cells during PTOA using transgenic reporter mice, multi-omic analyses, and in
vitro differentiation assays, and 2) characterize crosstalk between cWnt-active synovial fibroblasts and pro-
inflammatory macrophages, using knockout mice and crosstalk assays. To extend upon my molecular biology
and immunology expertise, I will receive rigorous technical and conceptual training from my diverse mentorship
committee during the K99 phase, and valuable career guidance. This expert training in bioinformatics; cWnt
signaling; bone, cartilage, and synovial biology; and multi-modal imaging, will be crucial for carrying out my
K99 aims and especially critical for successfully launching my independent career. These skills will be utilized
in my R00 phase to: 3) determine how Rspo2/Lgr signaling promotes osteophyte formation in PTOA, using
tissue-specific deletion and reporter mice, and in vitro differentiation assays. This work will significantly extend
our understanding of cellular and molecular mechanisms that underpin synovial fibrosis, inflammation, and
osteophyte formation in PTOA. These insights will have meaningful, tangible outcomes for human health, by
accelerating development of effective disease-modifying treatments for PTOA sufferers.
Public Health Relevance Statement
Post-traumatic osteoarthritis (PTOA) is a complex degenerative joint disease that arises after injury and is
characterized by pain, cartilage degradation, synovial inflammation and fibrosis, and formation of ectopic bone
growths called osteophytes. PTOA is a chronic, debilitating condition that affects millions worldwide, yet there
are currently no disease-modifying treatments. The overarching objective of this proposal is to
comprehensively characterize cells and processes responsible for PTOA progression and to provide insights
for the development of effective PTOA treatments that will meaningfully and tangibly improve patient
outcomes.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
073133571
UEI
GNJ7BBP73WE9
Project Start Date
01-May-2023
Project End Date
30-April-2025
Budget Start Date
01-May-2024
Budget End Date
30-April-2025
Project Funding Information for 2024
Total Funding
$103,080
Direct Costs
$95,444
Indirect Costs
$7,636
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$103,080
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5K99AR081894-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K99AR081894-02
Patents
No Patents information available for 5K99AR081894-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K99AR081894-02
Clinical Studies
No Clinical Studies information available for 5K99AR081894-02
News and More
Related News Releases
No news release information available for 5K99AR081894-02
History
No Historical information available for 5K99AR081894-02
Similar Projects
No Similar Projects information available for 5K99AR081894-02